Accudx Cq Triple Marker Ck-mb/ctni/yo Rapid Test Kit Pack Of 25 Tests Na

AccuDx Triple Marker CK-MB/cTnI/yo Fast Test Kit (Immunofluorescence Assay) is intended for in vitro quantitative determination of CK-MB/cTnl/Myoin serum, plasma or whole blood. This test is used as an aid in the clinical diagnosis, prognosis and evaluation of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome.

Creatine kinases are dimer isozymes composed of two monomer subunits, CK-M (for skeletal muscle derived) and CK-B (for brain derived), which can form al three combinations of monomers: CK-BB, CK-MM, and CK-MB. BB is found primarily in the brain. Skeletal muscles primarily contain the MM isoform, with trace amount of MB (around 1-4% of total CK activity). Cardiac muscles also contain the MM isoform, but higher amount of MB, typicaly around 20% of total CK activity. CK-MB is a more sensitive marker of
myocardial injury than total CK activity, because it has a lower basal level and a much narrower normal range. Medical literatures commonly state that CK-MB levels are elevated in 4 to 6 hours, peak at 10 to 24 hours, and return to normal within 3 to 4 days after an acute myocardial infarction. Classically, an increase of the myocardial-specific enzyme CK-MB is considered as the hallmark of acute myocardial infarction, and increased levels are frequently interpreted by the clinician as objective evidence of myocardial cell damage. Troponin complex consists of three regulatory proteins: T, which connects the troponin complex and tropomyosin (another cardiac muscle regulatory protein); I, which prevents muscle contraction in the absence of calcium; and C, which binds calcium. Cardiac troponin 1 (MW 22.5 kDa) and the two skeletal muscle isoforms of troponin I have considerable amino acid sequence homology, but cT contains an additional N-terminal sequence and is highly specific for myocardia.
Clinical studies have demonstrated the release of cTnl into the blood stream within hours following acute myocardial infarctions (AM) or ischemic damage. Elevated levels of cTnl are detectable in blood within 4 to 6 hours after the onset of chest pain, reaching peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. Due to the high myocardial specificity and the long duration of elevation, cTnl has become an important marker in the diagnosis and evaluation of patients
suspected of having an AMl. Myoglobin is a small monomeric protein which serves as an intracellular oxygen storage site. It is found in abundance in the muscle and can get through into the blood circulation directly when myocardial cell is damaged mildly. Therefore, myoglobin has been advocated as a sensitive marker fo early acute myocardial injury by American College of Cardiology Committee

PRINCIPLE
Mixed monoclonal antibodies against human CK-MB, cT and Myo are conjugated with fluorescence latex and another set of anti-human CK-MB/cTnI/Myo monoclonal antibodies were coated on different test lines respectively. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human CK-MB, cTnl and My monoclonal antibodies will bind with the CK-MB, cTnl and Myo in sample respectively and form marked antigen-antibody complexes. These complexes move to the test card detection zone by capillary action. Then marked antigen-anti- body complexes will be captured on different test lines by another set of
monoclonal antibodies against human CK-MB, cT or Myo respectively resulting in the accumulation of fluorescence particles on the test lines. The fluorescence intensity of each test line increases in proportion to the amount of CK-MB, cTnl or Myo in sample.
Then insert test card into ACCUDx CQ Immunofluorescence Quantitative Analyzer, the concentration of CK-MB, cT and Myo in sample will be measured and displayed on the screen. The value will be stored in ACCUDX CQ Analyzer and available for downloading.